Forty Seven, Inc. (FTSV) financial statements (2021 and earlier)

Company profile

Business Address 1490 O'BRIEN DRIVE, SUITE A
MENLO PARK, CA 94025
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:3291679911413915458
Cash and cash equivalents214321816112313
Short-term investments115135819812813145
Other undisclosed cash, cash equivalents, and short-term investments0(0)(0)0(0)(0) 
Deferred costs      4
Other undisclosed current assets811121177(1)
Total current assets:33817711112514616162
Noncurrent Assets
Operating lease, right-of-use asset22  
Property, plant and equipment1111111
Other noncurrent assets3312215
Other undisclosed noncurrent assets  32   
Total noncurrent assets:6655436
TOTAL ASSETS:34418411613014916368
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities182018111499
Accounts payable9384543
Accrued liabilities917107966
Debt11     
Other liabilities1      
Other undisclosed current liabilities3344246
Total current liabilities:23242215151414
Noncurrent Liabilities
Long-term debt and lease obligation3200000
Long-term debt, excluding current maturities2000000
Operating lease, liability11  
Other undisclosed noncurrent liabilities  22000
Total noncurrent liabilities:3222111
Total liabilities:26252417161415
Temporary equity, carrying amount      149
Stockholders' equity
Stockholders' equity attributable to parent31815891113133149(96)
Common stock0000000
Additional paid in capital5453592772762732725
Accumulated other comprehensive income (loss)0000(0)(0)(0)
Accumulated deficit(227)(201)(186)(163)(140)(123)(101)
Total stockholders' equity:31815891113133149(96)
TOTAL LIABILITIES AND EQUITY:34418411613014916368

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Gross profit: 16     
Operating expenses(25)(32)(24)(24)(18)(22)(17)
Operating loss:(25)(16)(24)(24)(18)(22)(17)
Nonoperating income (expense)
(Foreign Currency Transaction loss, before Tax)
(0)      
Other undisclosed loss from continuing operations before equity method investments, income taxes    (0)  
Loss before gain (loss) on sale of properties:(25)(16)(24)(24)(18)(22)(17)
Other undisclosed net income (loss)(2)  11  
Net loss:(26)(16)(24)(23)(17)(22)(17)
Other undisclosed net income attributable to parent 11  10
Net loss available to common stockholders, diluted:(26)(15)(23)(23)(17)(22)(17)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(26)(16)(24)(23)(17)(22)(17)
Comprehensive loss:(26)(16)(24)(23)(17)(22)(17)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0110(0)10
Comprehensive loss, net of tax, attributable to parent:(26)(15)(23)(23)(17)(22)(17)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: